Multi-target kinase-IN-10

Multi-target kinase-IN-10 (Compound 6l) 是一种口服有效、可穿过血脑屏障、选择性、可逆且竞争性的 MAO-B 抑制剂,其 IC50 为 0.0053 μM,可与底物竞争结合 MAO-B 的活性位点,螯合 Cu2+ 离子,抑制 Cu2+ 诱导的 ROS 生成,减少 NO、TNF-α、IL-1β 的释放,并可改善帕金森病。
产品编号: MS-C58643 CAS No.: 3022330-81-7 分子式: C17H13FN2O2 分子量: 296.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Multi-target kinase-IN-10 (Compound 6l) 是一种口服有效、可穿过血脑屏障、选择性、可逆且竞争性的 MAO-B 抑制剂,其 IC50 为 0.0053 μM,可与底物竞争结合 MAO-B 的活性位点,螯合 Cu2+ 离子,抑制 Cu2+ 诱导的 ROS 生成,减少 NO、TNF-α、IL-1β 的释放,并可改善帕金森病。

生物实验数据

生物活性 Multi-target kinase-IN-10 (Compound 6l) is an orally effective, blood-brain barrier-penetrant, selective, reversible, and competitive MAO-B inhibitor with an IC50 of 0.0053 μM that competes with the substrate for binding to the active site of MAO-B, chelates Cu2+ ions, inhibits Cu2+-induced ROS generation, reduces the release of NO, TNF-α, and IL-1β, and ameliorates Parkinson's disease.
IC50 & Target MAO-B:0.0053 μM
体外研究
(In Vitro)

Multi-target kinase-IN-10 可强效且选择性地抑制 MAO-B,其 IC50 为 0.0053 μM,选择性指数大于 1904.7。
Multi-target kinase-IN-10 (0.5-10.0 μM) 可剂量依赖性地抑制 BV-2 小胶质细胞中 LPS 诱导的 NO、TNF-α 和 IL-1β 的释放。
Multi-target kinase-IN-10 (2.5-10.0 μM) 可剂量依赖性地抑制 LPS 诱导的 BV-2 小胶质细胞内 ROS 生成,在 2.5 μM 和 10.0 μM 浓度下的抑制率分别为 18.9% 和 41.7%。

ELISA Assay

Cell Line: LPS-stimulated
BV-2 cells
Concentration: 0.5-10.0 μM
Incubation Time: Unclear
Result: Exhibited potent TNF-α suppression, with inhibition rates
of 35.0%, 56.4%, and 82.1% at 0.5, 2.5, 10.0 μM, respectively.
Exhibited IL-1β suppression, with inhibition rates
of 37.5%, 54.5%, and 75.2% at 0.5, 2.5, 10.0 μM, respectively.
体内研究
(In Vivo)

Multi-target kinase-IN-10 (灌胃,每日,剂量 7.5-37.5 mg/kg) 可显著促进 MPTP (MS-O89430) 诱导的亚急性帕金森病小鼠的行为学恢复、纹状体多巴胺水平恢复,降低氧化应激、减轻神经炎症并保护多巴胺能神经元。

Animal Model: C57BL/6 (10 per group, MPTP-induced subacute model)
Dosage: 7.5 mg/kg; 15 mg/kg; 37.5 mg/kg
Administration: i.g.; daily
Result: Significantly reduced motor deficits across all behavioral tests on days 1, 3, 7, and 14 at 37.5 mg/kg compared to the model group.
Showed significant improvements in most behavioral measures by day 7 at 15 mg/kg compared to the model group.
Showed a decreasing trend in motor deficits by day 3 and significant improvements by day 7 at 7.5 mg/kg compared to the model group.
Increased striatal dopamine levels by 60.5% at 37.5 mg/kg compared to the model group.
Reduced striatal malondialdehyde (MDA) content by 53.6% at 37.5 mg/kg compared to the model group.
Inhibited striatal TNF-α release by 67.1% and IL-6 release by 72.7% at 37.5 mg/kg relative to the model group.
Moderately restored dopamine levels, inhibited TNF-α release by 48.9%, and IL-6 release by 62.1% at 15 mg/kg compared to the model group.
Showed moderate dopamine recovery, inhibited TNF-α release by 24.2%, and IL-6 release by 45.8% at 7.5 mg/kg compared to the model group.
Significantly increased tyrosine hydroxylase (TH)-positive cell count in the substantia nigra pars compacta and enhanced TH-immunoreactive fiber density in the striatum at 37.5 mg/kg compared to the model group.

化学信息

分子量 296.30
分子式 C17H13FN2O2
CAS No. 3022330-81-7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础